Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FQ63V
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Xtandi 80 mg tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $4,169.59 with an ultimate completion date of July 28, 2025, was issued without a set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499,999,999 single-award vehicle valid through November 2026 that enables the agency to issue delivery orders for comprehensive pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
Xtandi is a prescription oncology medication used in the treatment of advanced prostate cancer. As a DLA-approved pharmaceutical supplier with an extensive portfolio of branded and generic prescription drugs, biologics, and medical consumables, DMS Pharmaceutical Group serves military and federal healthcare facilities across the nation. The company's consistent award history with the DLA demonstrates its established capability to provide reliable pharmaceutical distribution to government healthcare systems, positioning it as a critical component of the federal pharmaceutical supply chain supporting the Department of Defense's medical operations.
Quick answers
Who was awarded contract SPE2DB25FQ63V?
SPE2DB25FQ63V was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 25, 2025.
How much is contract SPE2DB25FQ63V worth?
The government has obligated $4,170 on SPE2DB25FQ63V.
Is contract SPE2DB25FQ63V an order under another contract?
Yes. SPE2DB25FQ63V is a delivery order under SPE2DB20D9226, an indefinite delivery contract.
Was contract SPE2DB25FQ63V competed?
The extent of competition for SPE2DB25FQ63V was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award